JP2024520020A - 肝疾患の治療における使用のためのペマフィブラートおよび／またはトホグリフロジン - Google Patents

肝疾患の治療における使用のためのペマフィブラートおよび／またはトホグリフロジン Download PDF

Info

Publication number
JP2024520020A
JP2024520020A JP2023572876A JP2023572876A JP2024520020A JP 2024520020 A JP2024520020 A JP 2024520020A JP 2023572876 A JP2023572876 A JP 2023572876A JP 2023572876 A JP2023572876 A JP 2023572876A JP 2024520020 A JP2024520020 A JP 2024520020A
Authority
JP
Japan
Prior art keywords
patient
pharma
score
acceptable salt
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572876A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520020A5 (cg-RX-API-DMAC10.html
Inventor
昇 金田
隆 大島
サンチタ ペンゼ，ショナ
亮平 谷川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Publication of JP2024520020A publication Critical patent/JP2024520020A/ja
Publication of JP2024520020A5 publication Critical patent/JP2024520020A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023572876A 2021-05-27 2022-05-25 肝疾患の治療における使用のためのペマフィブラートおよび／またはトホグリフロジン Pending JP2024520020A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163194088P 2021-05-27 2021-05-27
US63/194,088 2021-05-27
PCT/IB2022/054867 WO2022249071A1 (en) 2021-05-27 2022-05-25 Pemafibrate and/or tofogliflozin for use in treating liver disease

Publications (2)

Publication Number Publication Date
JP2024520020A true JP2024520020A (ja) 2024-05-21
JP2024520020A5 JP2024520020A5 (cg-RX-API-DMAC10.html) 2025-05-08

Family

ID=82020168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572876A Pending JP2024520020A (ja) 2021-05-27 2022-05-25 肝疾患の治療における使用のためのペマフィブラートおよび／またはトホグリフロジン

Country Status (10)

Country Link
US (1) US20240277745A1 (cg-RX-API-DMAC10.html)
EP (1) EP4346809B1 (cg-RX-API-DMAC10.html)
JP (1) JP2024520020A (cg-RX-API-DMAC10.html)
KR (1) KR20240013203A (cg-RX-API-DMAC10.html)
CN (1) CN117677385A (cg-RX-API-DMAC10.html)
AU (1) AU2022282651A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023024701A2 (cg-RX-API-DMAC10.html)
CA (1) CA3221073A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023013886A (cg-RX-API-DMAC10.html)
WO (1) WO2022249071A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2024014524A1 (cg-RX-API-DMAC10.html) * 2022-07-15 2024-01-18
CN115991682A (zh) * 2023-03-21 2023-04-21 广州佳途科技股份有限公司 一种培马贝特-d4的制备方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160136138A1 (en) * 2013-07-10 2016-05-19 Kowa Company, Ltd. Drug for treatment of nonalcoholic fatty liver disease
WO2018131626A1 (ja) * 2017-01-11 2018-07-19 興和株式会社 非アルコール性脂肪性肝疾患の予防及び治療薬

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160136138A1 (en) * 2013-07-10 2016-05-19 Kowa Company, Ltd. Drug for treatment of nonalcoholic fatty liver disease
WO2018131626A1 (ja) * 2017-01-11 2018-07-19 興和株式会社 非アルコール性脂肪性肝疾患の予防及び治療薬

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DIABETES FRONTIER, vol. 28, no. 5, JPN6026016155, 2017, pages 581 - 586, ISSN: 0005849656 *
DIABETES, vol. 67, Supplement_1, JPN6026016154, 2018, ISSN: 0005849655 *
HEPATOLOGY INTERNATIONAL, vol. Vol. 13, Supplement 1, JPN6026016156, February 2019 (2019-02-01), pages 208, ISSN: 0005849657 *
HEPATOLOGY, vol. 41, no. 6, JPN6026016157, 2005, pages 1313 - 1321, ISSN: 0005849658 *
INTERNAL MEDICINE, vol. 60, no. 14, JPN6026016152, 22 February 2021 (2021-02-22), pages 2167 - 2174, ISSN: 0005849653 *
SCIENTIFICREPORTS, vol. 10, no. 1, JPN6026016159, 2020, pages 1 - 10, ISSN: 0005849660 *
SCIENTIFICREPORTS, vol. 7, no. 1, JPN6026016158, 2017, pages 1 - 11, ISSN: 0005849659 *
YONAGO ACTA MEDICA, vol. 63, no. 3, JPN6026016153, 2020, pages 188 - 197, ISSN: 0005849654 *

Also Published As

Publication number Publication date
CN117677385A (zh) 2024-03-08
BR112023024701A2 (pt) 2024-02-15
AU2022282651A1 (en) 2023-12-07
KR20240013203A (ko) 2024-01-30
EP4346809A1 (en) 2024-04-10
CA3221073A1 (en) 2022-12-01
MX2023013886A (es) 2024-04-19
WO2022249071A1 (en) 2022-12-01
EP4346809B1 (en) 2026-07-15
US20240277745A1 (en) 2024-08-22

Similar Documents

Publication Publication Date Title
Gawrieh et al. Saroglitazar, a PPAR‐α/γ agonist, for treatment of NAFLD: a randomized controlled double‐blind phase 2 trial
US20240173333A1 (en) Treating Alagille Syndrome (ALGS)
EP4706756A2 (en) Semaglutide for the treatment of non-alcoholic steatohepatitis
JP7691971B2 (ja) レビー小体型認知症を処置するための組成物および方法
EP2861244B1 (en) Sleep apnea treatment
KR20240013203A (ko) 간 질환 치료에 사용하기 위한 페마피브레이트 및/또는 토포글리플로진
JP2019515895A (ja) インスリン抵抗性の治療におけるアゼライン酸エステル
TW202114654A (zh) 包含如sglt 1/2抑制劑的sglt抑制劑之治療
US8445467B2 (en) Reducing risk of type 2 diabetes (T2D)
JP2024539949A (ja) ボクセロトールを投与する方法
AU2018376904A1 (en) FXR agonists for the treatment of liver diseases
WO2015160249A2 (en) Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical composition as well as in pharmaceutical preparation
US20220347190A1 (en) Treatment comprising fxr agonists
EP4061368A1 (en) Methods of administering voxelotor
JP6042886B2 (ja) 早漏症治療用の薬学組成物
CN112823007A (zh) 用巴瑞替尼治疗原发性胆汁性胆管炎和原发性硬化性胆管炎
CA3034956C (en) TREATMENT OF NON-ALCOHOLIC HEPATIC STEATOSE
CN117462526A (zh) 一种大黄素琥珀酰酯类化合物在非酒精性脂肪肝病中的用途
WO2023202439A1 (zh) 二萜化合物衍生物或其盐在制备防治特应性皮炎的药物中的应用
CN118973562A (zh) 用于预防或减轻感染性疾病的一种或多种急性后症状的包含烟酰胺、烟酰胺前体、烟酰胺代谢物或其组合的组合物
Toto Treatment of dyslipidemia in chronic renal failure
Yagi et al. Efficacy and Safety of Once-daily Oxybutynin Patch in Patients with Overactive Bladder Who had Experienced Adverse Reactions Caused by Oral Antimuscarinic Drugs
Klonoff News from the FDA
HK40012462B (en) Treatment of nonalcoholic fatty liver disease
WO2015063602A1 (en) Desmopressin and blood glucose

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260623